NEO-X-PRIME Trademark

Trademark Overview

On Thursday, March 14, 2024, a trademark application was filed for NEO-X-PRIME with the United States Patent and Trademark Office. The USPTO has given the NEO-X-PRIME trademark a serial number of 79396585. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Wednesday, October 2, 2024. This trademark is owned by Alligator Bioscience AB. The NEO-X-PRIME trademark is filed in the Chemical Products, Pharmaceutical Products, and Computer & Software Services & Scientific Services categories with the following description:

Antibodies and libraries of antibodies for medical and pharmaceutical purposes; antibody formats, bispecific antibody formats, therapeutic antibodies, bispecific antibody formats and bispecific compounds for medical and pharmaceutical purposes; antibody formats, bispecific antibody formats, therapeutic antibodies, bispecific antibody formats and bispecific compounds for immuno-oncological applications; immuno-oncology preparations for medical and pharmaceutical purposes; antibodies; none of the aforesaid goods being for use in newborn screening and invitro.

Antibodies [for scientific and immuno-oncological use]; libraries and collections of antibodies; antibody formats; bispecific antibody formats, therapeutic antibodies; bispecific antibody formats for immuno-oncological applications; bispecific compounds; none of the aforesaid goods being for use in newborn screening and invitro.

Bio-technology and scientific research services relating to antibodies, antibody formats, bispecific antibody formats, therapeutic antibodies, and immune-oncology preparations; biochemical research and development in the field of antibodies, protein and enzyme; scientific laboratory services relating to antibodies, protein and enzyme; research, production and development services relating to antibody formats, bispecific antibody formats, therapeutic antibodies, bispecific antibody formats and bispecific compounds; research, development and production of immuno-oncology antibody preparations and pharmaceuticals; information, advisory and consultancy services relating to all of the aforesaid services; none of the aforesaid goods being for use in newborn screening and invitro.
neo-x-prime

General Information

Serial Number79396585
Word MarkNEO-X-PRIME
Filing DateThursday, March 14, 2024
Status641 - NON-FINAL ACTION - MAILED
Status DateWednesday, October 2, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesAntibodies and libraries of antibodies for medical and pharmaceutical purposes; antibody formats, bispecific antibody formats, therapeutic antibodies, bispecific antibody formats and bispecific compounds for medical and pharmaceutical purposes; antibody formats, bispecific antibody formats, therapeutic antibodies, bispecific antibody formats and bispecific compounds for immuno-oncological applications; immuno-oncology preparations for medical and pharmaceutical purposes; antibodies; none of the aforesaid goods being for use in newborn screening and invitro.
Goods and ServicesAntibodies [for scientific and immuno-oncological use]; libraries and collections of antibodies; antibody formats; bispecific antibody formats, therapeutic antibodies; bispecific antibody formats for immuno-oncological applications; bispecific compounds; none of the aforesaid goods being for use in newborn screening and invitro.
Goods and ServicesBio-technology and scientific research services relating to antibodies, antibody formats, bispecific antibody formats, therapeutic antibodies, and immune-oncology preparations; biochemical research and development in the field of antibodies, protein and enzyme; scientific laboratory services relating to antibodies, protein and enzyme; research, production and development services relating to antibody formats, bispecific antibody formats, therapeutic antibodies, bispecific antibody formats and bispecific compounds; research, development and production of immuno-oncology antibody preparations and pharmaceuticals; information, advisory and consultancy services relating to all of the aforesaid services; none of the aforesaid goods being for use in newborn screening and invitro.

Classification Information

International Class001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry.
US Class Codes001, 005, 006, 010, 026, 046
Class Status Code6 - Active
Class Status DateThursday, May 30, 2024
Primary Code001
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE
International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, May 30, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE
International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, May 30, 2024
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameAlligator Bioscience AB
Party Type10 - Original Applicant
Legal Entity Type98 - Unknown
AddressSE

Trademark Events

Event DateEvent Description
Thursday, May 30, 2024SN ASSIGNED FOR SECT 66A APPL FROM IB
Saturday, June 1, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, September 24, 2024ASSIGNED TO EXAMINER
Saturday, June 1, 2024APPLICATION FILING RECEIPT MAILED
Thursday, September 26, 2024NON-FINAL ACTION WRITTEN
Friday, September 27, 2024NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Wednesday, October 2, 2024NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Saturday, October 19, 2024REFUSAL PROCESSED BY IB
Wednesday, October 2, 2024REFUSAL PROCESSED BY MPU

Related Keywords

prime antibody formats bispecific antibodies immuno therapeutic services research relating compounds